Artivion (NYSE:AORT) Sets New 1-Year High – Here’s Why

Artivion, Inc. (NYSE:AORT)’s stock price reached a new 52-week high on Thursday . The company traded as high as $32.33 and last traded at $32.25, with a volume of 304340 shares. The stock had previously closed at $30.06.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AORT. Oppenheimer lifted their price objective on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a research note on Tuesday, December 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $34.00 price objective on shares of Artivion in a research note on Monday, December 9th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artivion has an average rating of “Buy” and a consensus price target of $31.80.

Artivion Stock Performance

The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -1,537.95 and a beta of 1.74. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The stock’s fifty day moving average is $28.82 and its two-hundred day moving average is $27.13.

Insider Activity at Artivion

In other Artivion news, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the completion of the transaction, the vice president now directly owns 33,503 shares of the company’s stock, valued at $1,005,090. The trade was a 18.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Amy Horton sold 4,329 shares of the company’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the transaction, the chief accounting officer now owns 135,660 shares in the company, valued at approximately $4,023,675.60. This represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,017 shares of company stock worth $600,007. Insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of institutional investors have recently made changes to their positions in AORT. Texas Permanent School Fund Corp lifted its holdings in Artivion by 14.5% during the 2nd quarter. Texas Permanent School Fund Corp now owns 39,063 shares of the company’s stock worth $1,002,000 after purchasing an additional 4,934 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Artivion by 59.6% during the second quarter. American Century Companies Inc. now owns 40,828 shares of the company’s stock worth $1,047,000 after buying an additional 15,252 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Artivion during the second quarter worth $331,000. Intech Investment Management LLC bought a new stake in shares of Artivion in the second quarter valued at about $253,000. Finally, RW Investment Management LLC bought a new position in Artivion during the second quarter worth about $219,000. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.